Authors:
I.A. VOLCHEGORSKY1, E.V. ROUND1, O.V. SOLYANNIKOVA1, V.S. RYKUN1, M.S. SUMINA2, V.N. DMITRIENKO2, E.V. BERDNIKOVA1
1Department of Pharmacology (Head - Prof. I.A. Volchegorsky) and Department of Eye Diseases (Head - V.S. Rykun) State Budgetary Educational Institution of Higher Professional Education "Chelyabinsk State Medical Academy" of the Ministry of Health and Social Development of the Russian Federation
2Microsurgery Department (Head - V.N. Dmitrienko) State Medical Healthcare Institution "Chelyabinsk Regional Clinical Hospital", Medgorodok
Place of publication:
EXPERIMENTAL AND CLINICAL PHARMACOLOGY, VOL. 75, No. 7, 2012, pp. 20-26
Abstract:
A prospective, randomized, single-blind, controlled study was conducted to evaluate the effect of domestically produced 3-hydroxypyridine and succinic acid derivatives (emoxipine, reamberin, and mexidol) on the efficacy of combination treatment for patients with primary open-angle glaucoma (POAG). Two-week intravenous administration of 3-hydroxypyridine derivatives (emoxipine and mexidol) was found to exert a retinoprotective effect 14 days after treatment initiation, with changes in central retinal artery (CRA) blood flow velocity delayed for 3 months. The rectinoprotective effect of emoxypine (a single dose of 150 mg) was manifested by a decrease in the horizontal dimensions of the blind spot after 2 weeks, followed by a decrease in end-diastolic CRA blood flow velocity 3 months after the end of infusion therapy. Mexidol (a single dose of 300 mg) administered 14 days after the start of treatment resulted in an expansion of the total visual field using a 16 mm2 test object, accompanied by a decrease in the optic nerve electrical sensitivity threshold and a reduction in the severity of POAG-associated hypothymia. Three months after the end of Mexidol administration, all blood flow velocity parameters in the central retinal artery increased. Reamberin (a single dose of 400 ml of a 1.5% Reamberin solution, a polyelectrolyte mixture containing meglumine sodium succinate) had no retinoprotective effect but caused proatherogenic changes in blood lipid profiles and a 3-month delayed increase in end-diastolic blood flow velocity in the central retinal artery. Mexidol, which is simultaneously a derivative of 3-oxypyridine and succinic acid, is superior to isolated derivatives of 3-oxypyridine (emoxipine) and succinic acid (reamberin) in terms of the severity of the retinoprotective effect, positive influence on the condition of the optic nerve and the mood of patients with POAG.
